Jounce Therapeutics Inc (JNCE)

NASDAQ
1.210
+0.020(+1.68%)
After Hours
1.210
0.000(0.00%)
- Real-time Data
  • Volume:
    575,189
  • Day's Range:
    1.190 - 1.260
  • 52 wk Range:
    0.577 - 8.800

JNCE Overview

Prev. Close
1.19
Day's Range
1.19-1.26
Revenue
-
Open
1.23
52 wk Range
0.577-8.8
EPS
-2.56
Volume
575,189
Market Cap
62.55M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,501,206
P/E Ratio
-0.47
Beta
1.21
1-Year Change
-83.36%
Shares Outstanding
51,694,237
Next Earnings Date
Mar 09, 2023
What is your sentiment on Jounce Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Jounce Therapeutics Inc News

Jounce Therapeutics Inc Analysis

Jounce Therapeutics Inc Company Profile

Jounce Therapeutics Inc Company Profile

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. The Company has developed a suite of integrated technologies that consist of its Translational Science Platform, enabling it to interrogate the cellular and molecular composition of tumors. Its program, JTX-8064, is a humanized IgG4, anti-LILRB2 monoclonal antibody designed to reprogram macrophages. JTX-8064 is being developed for patients with either PD-(L)1-inhibitor resistant or PD-(L)1 inhibitor-sensitive tumors. Vopratelimab is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator (ICOS). Pimivalimab is a clinical-stage anti-PD-1 monoclonal antibody that is being developed primarily for its use in combination with its product candidates.

Read More

Analyst Price Target

Average6.000 (+395.868% Upside)
High11.000
Low3.000
Price1.210
No. of Analysts5
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts Consensus

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellBuyBuyBuyStrong Sell
Technical IndicatorsSellStrong SellStrong BuyStrong BuyStrong Sell
SummarySellNeutralStrong BuyStrong BuyStrong Sell
  • Test Can Not SHORT 👉 Never Buy 👉 DELETE
    0
    • 🚀💰
      0
      • I was ready to dump this stock and was waiting for the 7.45 range so I can break even since May timeline...I never expected the good news today.. this will explode with big pharma investors...I was pleasantly surprised today with this news. this originally had a target price of 9.50 and it should be a good investment for 2021..so hold on for the ride! ..
        0
        • Worth 0.8B
          0
          • Gilead signs with Jnce and will pay $35m upfront in shares and later up to $685m royalties, great news for Jnce
            0
            • hello ! somebody have any new regarding JNCE, will it go up soon?
              0
              • target: $15
                0
                • Short this ?
                  1